Across TCGA pan-cancer cohorts, OR51N1P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of OR51N1P’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where OR51N1P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types OR51N1P is over-expressed in tumor.
PRAD are the cancer types where OR51N1P tumor–normal differential expression is most reproducible.